Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Enlitisa (Shanghai) Pharmaceutical Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, showing that the company's current filings are being reviewed in different specialized sections of the patent office. This separation requires the applicant to manage 2 independent prosecution tracks within the biotechnology field.
The busiest examiner for the company is HELLMAN, KRISTINA M, who is currently handling 1 busiest examiner pending action. With 2 pending actions distributed among 2 examiners, the workload is divided, meaning no single examiner controls the entirety of the pending portfolio. Practitioners should be prepared to address the specific requirements of each of the 2 art units, as the technical focus of each examiner may vary. This structure for 2 actions necessitates a review of how each examiner interprets the pharmaceutical claims at issue. By managing the 2 pending office actions independently, the company can address the specific technical requirements of each of the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316496 | CONJUGATES OF MONTELUKAST AND PEPTIDES | HELLMAN, KRISTINA M | 70d |
| 17781438 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18316496 | CONJUGATES OF MONTELUKAST AND PEPTIDES | HELLMAN, KRISTINA M | 1654 | §112 | Final Rejection | 70d | Pending | May 12, 2023 |
| 17781438 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | COFFA, SERGIO | 1658 | §112 | Final Rejection | — | Pending | Jun 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial